8-K

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                               ------------------

                                    FORM 8-K

             CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(D) OF
                       THE SECURITIES EXCHANGE ACT OF 1934


                                 DATE OF REPORT
                 (DATE OF EARLIEST EVENT REPORTED): JUNE 7, 2002


                        ENCHIRA BIOTECHNOLOGY CORPORATION
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)


         DELAWARE                        0-21130                  04-3078857

(STATE OR OTHER JURISDICTION OF   (COMMISSION FILE NUMBER)    (I.R.S. EMPLOYER
 INCORPORATION OR ORGANIZATION)                              IDENTIFICATION NO.)


                           4200 RESEARCH FOREST DRIVE
                           THE WOODLANDS, TEXAS 77381
                              (ADDRESS OF PRINCIPAL
                                EXECUTIVE OFFICES
                                  AND ZIP CODE)


                                 (281) 419-7000
                             (REGISTRANT'S TELEPHONE
                          NUMBER, INCLUDING AREA CODE)



                                ---------------

================================================================================



ITEM 5. OTHER EVENTS

      On June 7, 2002, Enchira Biotechnology Corporation (the "Company") issued
a press release announcing that the Nasdaq Stock Market has approved the
company's request to transfer its common stock to the Nasdaq SmallCap Market
from the Nasdaq National Market effective opening of business, June 7, 2002. The
stock will continue trading under the symbol ENBC. The company requested the
transfer to the Nasdaq SmallCap Market because it was unable to meet the $1.00
per share closing bid requirement of the Nasdaq National Market for the minimum
number of consecutive trading days. The Nasdaq SmallCap Market has the same
$1.00 closing bid requirement, but the company has until at least August 13,
2002 to demonstrate compliance with such requirement under Nasdaq SmallCap
Market rules for a period of at least ten consecutive trading days. If the
company fails to demonstrate compliance by August 13, 2002, the company may be
eligible for a grace period of 180 days after such date to demonstrate
compliance with the $1.00 closing bid requirement if the company is in
compliance with the Nasdaq SmallCap Market core listing standards.

      The press release is filed as an exhibit to this Current Report on Form
8-K and is incorporated by reference herein.

ITEM 7.  EXHIBITS

      Exhibit 99.1  -- Press Release





                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                              ENCHIRA BIOTECHNOLOGY CORPORATION

Date: June 7, 2002.

                              By:   /s/ PAUL G. BROWN, III
                                 ---------------------------------------------
                                    Paul G. Brown, III
                                    President, Chief Financial Officer and
                                    Vice President, Finance and Administration

EX-99.1

                                                                    EXHIBIT 99.1

CONTACT:
BMC Communications/Trout Group                 Enchira Biotechnology Corporation
Brad Miles x17 (for media inquiries)           Paul G. Brown, III
Jonathan Fassberg x16 (for investor inquiries) President
(212) 477-9007                                 (281) 364-6140


           NASDAQ APPROVES TRANSFER OF ENCHIRA BIOTECHNOLOGY STOCK
                            TO NASDAQ SMALLCAP MARKET

      THE WOODLANDS, TEXAS - JUNE 7, 2002 - Enchira Biotechnology Corporation
(NASDAQ: ENBC) today announced that the Nasdaq Stock Market has approved the
company's request to transfer its common stock to the Nasdaq SmallCap Market
from the Nasdaq National Market effective opening of business, June 7, 2002. The
stock will continue trading under the symbol ENBC. The company requested the
transfer to the Nasdaq SmallCap Market because it was unable to meet the $1.00
per share closing bid requirement of the Nasdaq National Market for the minimum
number of consecutive trading days. The Nasdaq SmallCap Market has the same
$1.00 closing bid requirement, but the company has until at least August 13,
2002 to demonstrate compliance with such requirement under Nasdaq SmallCap
Market rules for a period of at least ten consecutive trading days. If the
company fails to demonstrate compliance by August 13, 2002, the company may be
eligible for a grace period of 180 days after such date to demonstrate
compliance with the $1.00 closing bid requirement if the company is in
compliance with the Nasdaq SmallCap Market core listing standards.

      Paul G. Brown, III, President of Enchira noted, "We are extremely pleased
that Nasdaq has approved our move to the Small Cap Market, thus enabling our
shareholders to continue to trade their shares thru the Nasdaq Stock Market. We
are hopeful that this decision will provide us the necessary time to explore
strategic alternatives or come into compliance."

      Enchira Biotechnology is a drug discovery and development company engaged
in the development of Anti-Cancer Ligand (ACL(TM)) proteins that bloCk validated
receptor tyrosine kinase targets implicated in the most aggressive forms of
cancer. Additional information is available at the Company's website:
http://www.enchira.com.

      THIS DOCUMENT CONTAINS FORWARD-LOOKING STATEMENTS RELATING TO THE
CONTINUED LISTING OF THE COMPANY'S STOCK ON THE NASDAQ NATIONAL AND SMALL CAP
MARKETS, THE DISCOVERY AND DEVELOPMENT OF MOLECULES FOR TREATING VARIOUS
DISEASES, AND POTENTIAL STRATEGIC TRANSACTIONS, THAT ARE SUBJECT TO CERTAIN
RISKS, UNCERTAINTIES AND ASSUMPTIONS, INCLUDING BUT NOT LIMITED TO, THE ABILITY
TO SUCCESSFULLY REDEPLOY THE COMPANY'S ASSETS IN A TIMELY MANNER AND TO REALIZE
VALUE FOR THE COMPANY'S ASSETS. SHOULD THESE RISKS AND UNCERTAINTIES
MATERIALIZE, OR SHOULD UNDERLYING ASSUMPTIONS PROVE INCORRECT, ACTUAL RESULTS
MAY VARY MATERIALLY FROM THOSE INDICATED IN SUCH FORWARD-LOOKING STATEMENTS. FOR
A DISCUSSION OF CERTAIN ADDITIONAL RISKS AND ASSUMPTIONS, SEE "RISK FACTORS"
INCLUDED IN THE COMPANY'S SEC FILINGS.

SOURCE: Enchira Biotechnology Corporation